Although tumor targeting is almost equal at 20–24 and 44–48 h after injection, PSMA-GCK01 initially demonstrates a higher liver-to-kidney uptake ratio, which translates into better delineation of the intestine 48 h after injection, possibly implying a slight shift from renal to hepatointestinal clearance for PSMA-GCK01 compared with PSMA-617. The gene discussed is FOLH1; the disease is neoplasm.